Dec 1, 2022RecruitingNCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaNCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...